KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Non-Current Liabilities (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Total Non-Current Liabilities for 15 consecutive years, with $14.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 50.53% to $14.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.6 million through Dec 2025, down 50.53% year-over-year, with the annual reading at $14.6 million for FY2025, 50.53% down from the prior year.
  • Total Non-Current Liabilities hit $14.6 million in Q4 2025 for Arbutus Biopharma, up from $9.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $67.4 million in Q1 2022 to a low of $9.3 million in Q3 2025.
  • Historically, Total Non-Current Liabilities has averaged $31.3 million across 5 years, with a median of $30.3 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 429.71% in 2022 and later tumbled 67.93% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $18.8 million in 2021, then soared by 172.19% to $51.0 million in 2022, then tumbled by 39.68% to $30.8 million in 2023, then fell by 4.13% to $29.5 million in 2024, then crashed by 50.53% to $14.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ABUS at $14.6 million in Q4 2025, $9.3 million in Q3 2025, and $9.5 million in Q2 2025.